Konstantin Demir
Research Subjects
Konstantin Demir has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Britta Statz
Hopp Children’s Cancer Center Heidelberg (KiTZ), Im Neuenheimer Feld 430, 69120 Heidelberg, Germany
1 shared publication - Emmanuelle Claude
Waters Corporation, Wilmslow SK9 4AX, UK
1 shared publication - Joshua Raoul Lindner
Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
1 shared publication - Julia Benzel
Hopp Children’s Cancer Center Heidelberg (KiTZ), Im Neuenheimer Feld 430, 69120 Heidelberg, Germany
1 shared publication - Julia Sundheimer
Hopp Children’s Cancer Center Heidelberg (KiTZ), Im Neuenheimer Feld 430, 69120 Heidelberg, Germany
1 shared publication - Jürgen Burhenne
Heidelberg University
1 shared publication
Latest Publications
- Open Access
- 1 June 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 694
Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections
Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from solid surfaces at atmospheric pressure, without the addition of organic compounds to initiate desorption. However, severe drawbacks from former DESI hardware stability made the development of assays for drug quantification difficult. In the present study, the potential of new prototype source setups (High Performance DESI Sprayer and Heated Transfer Line) for the development of drug quantification assays in tissue sections was evaluated. It was demonstrated that following dedicated optimization, new DESI XS enhancements present promising options regarding targeted quantitative analyses. As a model compound for these developments, ulixertinib, an inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2 was used.
- 1 June 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 694
Open AccessAnalytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections
Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from solid surfaces at atmospheric pressure, without the addition of organic compounds to initiate desorption. However, severe drawbacks from former DESI hardware stability made the development of assays for drug quantification difficult. In the present study, the potential of new prototype source setups (High Performance DESI Sprayer and Heated Transfer Line) for the development of drug quantification assays in tissue sections was evaluated. It was demonstrated that following dedicated optimization, new DESI XS enhancements present promising options regarding targeted quantitative analyses. As a model compound for these developments, ulixertinib, an inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2 was used.